Changes in nutritional status and body composition during enzyme replacement therapy in adult-onset type II glycogenosis.
BACKGROUND
In adult glycogen storage disease type II (GSDII), a single-gene mutation causes reduction of the lysosomal enzyme acid alpha-glucosidse. This produces a chronic proximal myopathy with respiratory involvement. Enzyme replacement treatment (ERT) has recently become available and is expected to improve muscle strength. This should result in increased lean body mass. In this study we evaluate body composition and nutritional status in GSDII, and assess whether these parameters changed during treatment.


METHODS
Seventeen patients with late-onset GSDII, aged 52.6 +/- 16.8 years, received ERT for >18 months. Dietary habits and metabolic profiles of glucids, lipids, and proteins were assessed. Body composition was calculated using anthropometry and bioelectrical impedence analysis.


RESULTS
On inclusion, we found increased fat mass (FM) in five patients in severe disease stage; all had normal body mass index (BMI). FM correlated inversely, and lean mass (LM) directly, with creatine kinase, prealbumin and albumin levels. After treatment, BMI and FM significantly increased, while LM only showed a trend toward increase. Prealbumin and albumin levels increased as early as after the first months of ERT.


CONCLUSIONS
Body mass index value may underestimate FM in patients in severe stage of disease, due to altered body composition. In severely affected patients, laboratory parameters revealed a relative protein malnutrition, that was reversed by ERT, this reflecting restoration of normal muscle metabolic pathways. Increased BMI may indicate a reduction in energy consumption during exercise or respiration, along with clinical improvement.
Institute of Neurology C. Mondino, University of Pavia, Pavia, Italy. sabrina.ravaglia@mondino.it
S
S
Ravaglia
C
C
Danesino
A
A
Moglia
A
A
Costa
H
H
Cena
L
L
Maccarini
A
A
Carlucci
A
A
Pichiecchio
P
P
Bini
P
P
De Filippi
M
M
Rossi
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000032:analysis / Q000378:metabolism; D001823:Body Composition / Q000187:drug effects / Q000502:physiology; D056947:Enzyme Replacement Therapy / Q000379:methods*; D005260:Female; D006009:Glycogen Storage Disease Type II / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D009752:Nutritional Status / Q000187:drug effects* / Q000502:physiology; D011506:Proteins / Q000032:analysis / Q000378:metabolism
D015415:Biomarkers; D011506:Proteins